US OptionsDetailed Quotes

ZLAB250516P17500

Watchlist

0.00
0.000.00%

15min DelayClose Apr 28 09:30 ET

0.00High0.00Low

Zai Lab Stock Discussion

Teddy123

Yesterday 10:57

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

$Zai Lab (ZLAB.US)$
Breakthrough: Zai Lab's Dual Cancer Therapies Show Promise in Resistant Tumors at AACR 2025

Teddy123

Apr 23 22:57

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

$Zai Lab (ZLAB.US)$
Breakthrough Lung Cancer Drug Data: New DLL3-Targeted ADC Trial Results Coming at ASCO 2025

Teddy123

Apr 21 19:49

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

$Zai Lab (ZLAB.US)$
First NTRK Cancer Treatment in China: NMPA Fast-Tracks Repotrectinib Review for Untreated Patient Market

103818967

Apr 4 22:50

$Zai Lab (ZLAB.US)$ why is this dropping when tariffs does not apply to pharmaceutical?

Teddy123

Mar 13 09:58

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

$Zai Lab (ZLAB.US)$
China Accepts TIVDAK Application: 45% Lower Death Risk in Cervical Cancer Trial

Sean Parker

Jan 23 16:01

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

$Zai Lab (ZLAB.US)$
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has received Orphan Drug Designation (ODD) from the U.S. FDA for ZL-1310, their first-in-class DLL3 antibody-drug conjugate (ADC) designed to treat small cell lung cancer (SCLC). The designation comes after promising results from an ongoing Phase 1a/1b study in patients with previously treated extensive-stage SCL...